Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pharmatek Announces Acquisition of Additional Xcelodose® 600S System

Published: Thursday, February 07, 2013
Last Updated: Wednesday, February 06, 2013
Bookmark and Share
Acquisition enables increased capacity to meet growing demand for powder in a capsule.

Pharmatek has announced that it has purchased another Xcelodose® 600S system.

This acquisition doubles the company's manufacturing production rate for powder-in-capsule (PIC) operations and increases overall preclinical and early phase clinical cGMP supply capabilities.

"The acquisition of an additional Xcelodose® unit enables Pharmatek to better serve our clients' early phase development strategies and meet the growing demand for PIC projects," stated Kevin Rosenthal, Director of Manufacturing at Pharmatek.

Rosenthal continued, "For PIC applications, the Xcelodose® can drastically decrease time to clinic while also lowering the cost of drug product for first-in-human trials."

In addition to adding another Xcelodose® system, Pharmatek has implemented a dedicated Xcelodose® project team to ensure the overall success and quick turnaround of PIC programs.

Each team is led by an Xcelodose® engineer who oversees the project from planning to execution.

The Xcelodose®, manufactured by Capsugel, is a precision powder micro-doser and automated encapsulator that has the ability to fill formulations or active pharmaceutical ingredient (API) directly into capsules with a remarkable level of accuracy.

The Xcelodose® can measure to levels as low as 100 micrograms and can dispense into capsules from size 00 to 4. Dosing directly into capsules can reduce the amount of API required.

Additionally, the unit minimizes overall development time by simplifying analytical and stability protocols.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pharmatek Expands Spray Drying Capabilities
New spray dryer strengthens the Company’s portfolio of solutions for poorly soluble compounds.
Friday, May 22, 2015
Pharmatek Expands Packaging Services
Installation and qualification of an automated bottling line at San Diego facility.
Thursday, October 17, 2013
CMO Laboratory Expands GMP Manufacturing Capabilities
Pharmatek Laboratories, Inc. have announced that it has added roller compaction to its solid oral dosage form manufacturing capabilities. The company has purchased two roller compactors, a pilot-scale. Both machines have been integrated into Pharmatek’s GMP facility and are ready for GMP manufacturing.
Thursday, November 25, 2010
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!